{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:44:22Z","timestamp":1783039462449,"version":"3.54.6"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Irritable bowel syndrome (IBS) is a common disorder associated with high healthcare costs and reduced quality of life. The long-term safety of its pharmacotherapies remains unclear. This study aims to assess the association between long-term pharmacotherapies and all-cause mortality in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study using a nationwide U.S. electronic health record database (January 1, 2005, to January 1, 2023). A 1:1 propensity score-matched cohort included 669,083 adults (aged 18\u201365) with IBS. Patients were grouped by pharmacotherapy use, with subgroup analyses for IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C). Follow-up started at the time of medication prescription after diagnosis. Exposures included guideline-recommended therapies for IBS, IBS-D, or IBS-C. The primary outcome was all-cause mortality, assessed using Cox proportional hazards models and target trial emulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Antidepressant use is associated with an increased risk of all-cause mortality (hazard ratio [HR], 1.35; 95% CI, 1.26\u20131.45; mortality rate, 1.6% vs. 1.0%). This association remains consistent across antidepressant subclasses and demographic subgroups. Antispasmodic use is not linked to increased mortality (HR, 0.95; 95% CI, 0.89\u20131.00). For IBS-D, cholestyramine\/colestipol, eluxadoline, and rifaximin are not associated with mortality. However, diphenoxylate (HR, 1.89; 95% CI, 1.02\u20133.51) and loperamide (HR, 2.39; 95% CI, 1.48\u20133.90) show increased mortality risk. For IBS-C, polyethylene glycol-3350 and secretagogues have no significant association with mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings raise concerns regarding the safety of antidepressants and mu receptor agonists in IBS treatment and underscore the need for cautious prescribing and further research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01498-6","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:02:22Z","timestamp":1775638942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome"],"prefix":"10.1038","volume":"6","author":[{"given":"Sepideh","family":"Mehravar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-5954","authenticated-orcid":false,"given":"Yee Hui","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnian","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0106-372X","authenticated-orcid":false,"given":"Ali","family":"Rezaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"1498_CR1","first-page":"332","volume":"108","author":"F Mearin","year":"2016","unstructured":"Mearin, F. et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev. Esp. Enferm. Dig. 108, 332\u201363 (2016).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"1498_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.2015.0954","volume":"313","author":"WD Chey","year":"2015","unstructured":"Chey, W. D., Kurlander, J. & Eswaran, S. Irritable bowel syndrome: a clinical review. JAMA 313, 949\u2013958 (2015).","journal-title":"JAMA"},{"key":"1498_CR3","first-page":"71","volume":"6","author":"C Canavan","year":"2014","unstructured":"Canavan, C., West, J. & Card, T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 6, 71\u201380 (2014).","journal-title":"Clin. Epidemiol."},{"key":"1498_CR4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(20)31548-8","volume":"396","author":"AC Ford","year":"2020","unstructured":"Ford, A. C., Sperber, A. D., Corsetti, M. & Camilleri, M. Irritable bowel syndrome. Lancet 396, 1675\u20131688 (2020).","journal-title":"Lancet"},{"key":"1498_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/CEG.S464375","volume":"17","author":"MA Sendzischew Shane","year":"2024","unstructured":"Sendzischew Shane, M. A. et al. Review of the patient burden and therapeutic landscape of irritable bowel syndrome with constipation in the United States. Clin. Exp. Gastroenterol. 17, 227\u2013253 (2024).","journal-title":"Clin. Exp. Gastroenterol."},{"key":"1498_CR6","unstructured":"Xifaxan\u00ae (rifaximin) tablets, for oral use [package insert]. Bridgewater: Salix Pharmaceuticals; (2018)."},{"key":"1498_CR7","unstructured":"Viberzi (eluxadoline) tablets, for oral use, CIV [package insert]. Madison: Allergan USA, Inc. (2018)."},{"key":"1498_CR8","unstructured":"Lotronex\u00ae (alosetron hydrochloride) tablets [package insert]. Roswell: Sebela Pharmaceuticals Inc. (2016)."},{"key":"1498_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.gastro.2019.10.036","volume":"158","author":"V Rangan","year":"2020","unstructured":"Rangan, V. et al. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey. Gastroenterology 158, 786\u2013788.e1 (2020).","journal-title":"Gastroenterology"},{"key":"1498_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.gastro.2022.04.016","volume":"163","author":"L Chang","year":"2022","unstructured":"Chang, L. et al. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology 163, 118\u2013136 (2022).","journal-title":"Gastroenterology"},{"key":"1498_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","volume":"163","author":"A Lembo","year":"2022","unstructured":"Lembo, A. et al. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology 163, 137\u2013151 (2022).","journal-title":"Gastroenterology"},{"key":"1498_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2021","unstructured":"Lacy, B. E. et al. ACG clinical guideline: management of irritable bowel syndrome. Am. J. Gastroenterol. 116, 17\u201344 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"1498_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","volume":"70","author":"DH Vasant","year":"2021","unstructured":"Vasant, D. H. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 70, 1214 (2021).","journal-title":"Gut"},{"key":"1498_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.14309\/ajg.0000000000002800","volume":"119","author":"I Hanna-Jairala","year":"2024","unstructured":"Hanna-Jairala, I. & Drossman, D. A. Central neuromodulators in irritable bowel syndrome: Why, How, and When. Am. J. Gastroenterol. 119, 1272\u20131284 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"1498_CR15","unstructured":"TriNetX: Global Health Research Network. https:\/\/www.trinetx.com"},{"key":"1498_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/00365521.2023.2173021","volume":"58","author":"NT Tornkvist","year":"2023","unstructured":"Tornkvist, N. T. et al. Identification of irritable bowel syndrome in the Swedish National Patient Register: a validation study. Scand. J. Gastroenterol. 58, 709\u2013717 (2023).","journal-title":"Scand. J. Gastroenterol."},{"key":"1498_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-023-00480-z","volume":"22","author":"LM Garcia-Marin","year":"2023","unstructured":"Garcia-Marin, L. M. et al. Discontinuation of antidepressant treatment: a retrospective cohort study on more than 20,000 participants. Ann. Gen. Psychiatry 22, 49 (2023).","journal-title":"Ann. Gen. Psychiatry"},{"key":"1498_CR18","doi-asserted-by":"crossref","unstructured":"Sheu, J-. Y. et al. The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients. Nat. Commun. 15, 10043 (2024).","DOI":"10.1038\/s41467-024-54171-8"},{"key":"1498_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Using Big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u201364 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"1498_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMp2113319","volume":"385","author":"MA Hern\u00e1n","year":"2021","unstructured":"Hern\u00e1n, M. A. Methods of public health research - strengthening causal inference from observational data. N. Engl. J. Med. 385, 1345\u20131348 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1498_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2012.96867","volume":"309","author":"V Prasad","year":"2013","unstructured":"Prasad, V. & Jena, A. B. Prespecified falsification end points can they validate true observational associations?. JAMA 309, 241\u2013242 (2013).","journal-title":"JAMA"},{"key":"1498_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat. Med. 30, 168\u2013176 (2024).","journal-title":"Nat. Med."},{"key":"1498_CR23","doi-asserted-by":"publisher","first-page":"746","DOI":"10.14309\/ajg.0000000000000573","volume":"115","author":"K Staller","year":"2020","unstructured":"Staller, K. et al. Mortality risk in irritable bowel syndrome: results from a nationwide prospective cohort study. Am. J. Gastroenterol. 115, 746\u2013755 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000477940","volume":"86","author":"MM Maslej","year":"2017","unstructured":"Maslej, M. M. et al. The mortality and myocardial effects of antidepressants are moderated by preexisting cardiovascular disease: a meta-analysis. Psychother. Psychosom. 86, 268\u2013282 (2017).","journal-title":"Psychother. Psychosom."},{"key":"1498_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00228-020-03049-x","volume":"77","author":"M Elsayed","year":"2021","unstructured":"Elsayed, M. et al. Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. Eur. J. Clin. Pharm. 77, 767\u2013775 (2021).","journal-title":"Eur. J. Clin. Pharm."},{"key":"1498_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2125.2009.03496.x","volume":"68","author":"K Jolly","year":"2009","unstructured":"Jolly, K. et al. Sudden death in patients receiving drugs tending to prolong the QT interval. Br. J. Clin. Pharm. 68, 743\u201351 (2009).","journal-title":"Br. J. Clin. Pharm."},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"704281","DOI":"10.3389\/fcvm.2021.704281","volume":"8","author":"A Calvi","year":"2021","unstructured":"Calvi, A. et al. Antidepressant drugs effects on blood pressure. Front. Cardiovasc. Med. 8, 704281 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"1498_CR28","first-page":"533","volume":"13","author":"J Volpi-Abadie","year":"2013","unstructured":"Volpi-Abadie, J., Kaye, A. M. & Kaye, A. D. Serotonin syndrome. Ochsner J. Winter 13, 533\u201340 (2013).","journal-title":"Ochsner J. Winter"},{"key":"1498_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.annepidem.2019.04.010","volume":"35","author":"MM Glymour","year":"2019","unstructured":"Glymour, M. M. et al. Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding. Ann. Epidemiol. 35, 42\u201347.e1 (2019).","journal-title":"Ann. Epidemiol."},{"key":"1498_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02247-x","volume":"20","author":"RM Joseph","year":"2022","unstructured":"Joseph, R. M. et al. The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records. BMC Med. 20, 43 (2022).","journal-title":"BMC Med."},{"key":"1498_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/thorax-2022-219736","volume":"79","author":"RA Siraj","year":"2024","unstructured":"Siraj, R. A., Bolton, C. E. & McKeever, T. M. Association between antidepressants with pneumonia and exacerbation in patients with COPD: a self-controlled case series (SCCS. Thorax 79, 50\u201357 (2024).","journal-title":"Thorax"},{"key":"1498_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/1060028016644466","volume":"50","author":"ZA Marcum","year":"2016","unstructured":"Marcum, Z. A. et al. Antidepressant use and recurrent falls in community-dwelling older adults: findings from the health ABC study. Ann. Pharmacother. 50, 525\u201333 (2016).","journal-title":"Ann. Pharmacother."},{"key":"1498_CR33","doi-asserted-by":"publisher","first-page":"b2880","DOI":"10.1136\/bmj.b2880","volume":"339","author":"M Stone","year":"2009","unstructured":"Stone, M. et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339, b2880 (2009).","journal-title":"BMJ"},{"key":"1498_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/ajg.2014.82","volume":"109","author":"R Anglin","year":"2014","unstructured":"Anglin, R. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am. J. Gastroenterol. 109, 811\u20139 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"1498_CR35","doi-asserted-by":"publisher","first-page":"1464898","DOI":"10.3389\/fpsyt.2024.1464898","volume":"15","author":"C Lassale","year":"2024","unstructured":"Lassale, C. et al. Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study. Front. Psychiatry 15, 1464898 (2024).","journal-title":"Front. Psychiatry"},{"key":"1498_CR36","doi-asserted-by":"crossref","unstructured":"Kahn, L., Kriikku, P. & J\u00f6nsson, A. Loperamide positive deaths in Sweden 2012-2022 and Finland 2017-2022: fatal loperamide intoxication exclusively for Sweden. Forensic Sci. Int. 361, 112130 (2024).","DOI":"10.1016\/j.forsciint.2024.112130"},{"key":"1498_CR37","first-page":"S11","volume":"7","author":"DE Baker","year":"2007","unstructured":"Baker, D. E. Loperamide: a pharmacological review. Rev. Gastroenterol. Disord. 7, S11\u20138 (2007).","journal-title":"Rev. Gastroenterol. Disord."},{"key":"1498_CR38","doi-asserted-by":"publisher","unstructured":"Swank, K. A., Wu, E., Kortepeter, C., McAninch, J. & Levin, R. L. Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse. J. Am. Pharm. Assoc. 57, S63-s67. https:\/\/doi.org\/10.1016\/j.japh.2016.11.011 (2017).","DOI":"10.1016\/j.japh.2016.11.011"},{"key":"1498_CR39","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00210-016-1286-7","volume":"389","author":"J Kang","year":"2016","unstructured":"Kang, J., Compton, D. R., Vaz, R. J. & Rampe, D. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. Naunyn Schmiedebergs Arch. Pharm. 389, 1133\u20137 (2016).","journal-title":"Naunyn Schmiedebergs Arch. Pharm."},{"key":"1498_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.annemergmed.2017.04.008","volume":"70","author":"PE Wu","year":"2017","unstructured":"Wu, P. E. & Juurlink, D. N. Clinical review: loperamide toxicity. Ann. Emerg. Med 70, 245\u2013252 (2017).","journal-title":"Ann. Emerg. Med"},{"key":"1498_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0972-5229.173685","volume":"20","author":"KM Gulla","year":"2016","unstructured":"Gulla, K. M. & Sachdev, A. Illness severity and organ dysfunction scoring in Pediatric Intensive Care Unit. Indian J. Crit. Care Med. 20, 27\u201335 (2016).","journal-title":"Indian J. Crit. Care Med."},{"key":"1498_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund, J. L., Richardson, D. B. & St\u00fcrmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2, 221\u2013228 (2015).","journal-title":"Curr. Epidemiol. Rep."},{"key":"1498_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/pds.1360","volume":"16","author":"H Tamim","year":"2007","unstructured":"Tamim, H., Monfared, A. A. & LeLorier, J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol. Drug Saf. 16, 250\u20138 (2007).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1498_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40471-014-0027-z","volume":"1","author":"MJ Funk","year":"2014","unstructured":"Funk, M. J. & Landi, S. N. Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. Curr. Epidemiol. Rep. 1, 175\u2013185 (2014).","journal-title":"Curr. Epidemiol. Rep."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01498-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:02:25Z","timestamp":1775638945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01498-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These authors disclose the following: Mark Pimentel is also a consultant for and received grant support from Bausch Health. Ali Rezaie reports serving as a consultant for Bausch Health and Ardelyx. In addition, Cedars-Sinai Medical Center has a licensing agreement with Gemelli Biotech. Ali Rezaie and Mark Pimentel have equity in Gemelli Biotech and Good LFE. The remaining authors disclose no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}